Newsroom | Co-Diagnostics, Inc.

Press Releases

Newsroom

Press Releases

In the News

Media Resources

Month Year

Media Resources

Dec 19, 2017

Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities

SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today...
Dec 12, 2017

Co-Diagnostics, Inc. Announces Sale of Molecular Diagnostic Tests, Including Zika Virus, to Major Caribbean Laboratory

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Nov 15, 2017

Co-Diagnostics, Inc. Reports Q3 Financial Results and Updates Corporate Developments

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Nov 7, 2017

Co-Diagnostics, Inc. Manufacturing Joint Venture Breaks Ground in India

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, and...
Nov 2, 2017

Co-Diagnostics, Inc. Granted ISO 13485:2016 Certification

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, has been...
Oct 31, 2017

Co-Diagnostics, Inc. Products to Be Presented at Fair of Havana 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Oct 16, 2017

Co-Diagnostics, Inc. to Present Zika Tests to Dominican Republic Ministry of Health

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Sep 25, 2017

Co-Diagnostics, Inc. to Present at Robins Equity Research Roundup 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Sep 7, 2017

Co-Diagnostics, Inc. to Present at NewsMakers Conference 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Sep 5, 2017

Co-Diagnostics, Inc. to Sign Purchase Agreement with MEDCIS Pathlabs

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, and MEDCIS...
Aug 24, 2017

Co-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin

Sales expected upon successful performance evaluation and validation

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Aug 21, 2017

Co-Diagnostics, Inc. CEO to Present at 2017 SALSS

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced...
Aug 10, 2017

Co-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit

Audit to prepare for eventual sales into the US market

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, will be...
Aug 2, 2017

Co-Diagnostics, Inc. to Attend AACC 2017

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, will be...
Jul 27, 2017

Co-Diagnostics, Inc. Verifies Zika CoPrimer™ Test

SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ:CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary...
Jul 25, 2017

Co-Diagnostics, Inc. Announces Joint Venture in India

SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, officially...
Jul 17, 2017

Co-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

Sandy, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the...
Jul 12, 2017

Co-Diagnostics, Inc. Announces Pricing of IPO

Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic...

Show per page

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

Site Terms and Conditions

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa